EU/3/11/896

About

On 30 August 2011, orphan designation (EU/3/11/896) was granted by the European Commission to Lamellar Biomedical Ltd, United Kingdom, for multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol for treatment of cystic fibrosis.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in November 2019.

Key facts

Active substance
Multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol
Disease / condition
Treatment of cystic fibrosis
Date of first decision
30/08/2011
Outcome
Positive
EU designation number
EU/3/11/896

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Clinical Network Services (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
The Netherlands
Tel. +31 2089 49169
E-mail: cns@clinical.net.au

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating